[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZuOK6Pf28LkQozPpQGq5HVqfu0J7czBo1SMzuVH7OuM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"Newcastle-upon-Tyne Hospitals NHS Trust",[4],67,false,6,4,113360,2,47,[14,17,19,21,23,25,27,30],{"name":15,"count":16},"Rheumatoid Arthritis",3,{"name":18,"count":11},"Parkinson's Disease",{"name":20,"count":11},"Type 2 Diabetes Mellitus",{"name":22,"count":11},"Healthy",{"name":24,"count":11},"Mitochondrial Diseases",{"name":26,"count":11},"Acute Coronary Syndrome",{"name":28,"count":29},"Hearing Loss",1,{"name":31,"count":29},"Cytomegalovirus",[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06978985","Adult SMA Research and Clinical Hub","2027-04-30","Risdiplam",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,70,88,115,140,165,193,218,246,264,282,308,333,358,376,403,421,451,469,487,505,523,541,559,586,604,630,648,671,698,723,748,775],{"intervention":37,"totalTrials":29,"cells":47},{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":57,"NA":59},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[],{"trials":54,"activeCount":50},[],{"trials":56,"activeCount":50},[],{"trials":58,"activeCount":50},[],{"trials":60,"activeCount":29,"soonestReadout":36},[61],{"nctId":34,"briefTitle":35,"status":62,"phases":63,"primaryCompletion":36,"completion":36,"start":64,"enrollment":65,"conditions":66,"interventions":68},"RECRUITING",[],"2022-07-29",600,[67],"Spinal Muscular Atrophy (SMA)",[37,69],"Nusinersen Injectable Product",{"intervention":69,"totalTrials":29,"cells":71},{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":82},{"trials":73,"activeCount":50},[],{"trials":75,"activeCount":50},[],{"trials":77,"activeCount":50},[],{"trials":79,"activeCount":50},[],{"trials":81,"activeCount":50},[],{"trials":83,"activeCount":29,"soonestReadout":36},[84],{"nctId":34,"briefTitle":35,"status":62,"phases":85,"primaryCompletion":36,"completion":36,"start":64,"enrollment":65,"conditions":86,"interventions":87},[],[67],[37,69],{"intervention":89,"totalTrials":29,"cells":90},"clopidogrel",{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":113},{"trials":92,"activeCount":50},[],{"trials":94,"activeCount":50},[],{"trials":96,"activeCount":50},[],{"trials":98,"activeCount":50},[],{"trials":100,"activeCount":50},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT00728156","Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)","COMPLETED",[43],"2010-12","2012-04","2009-08",90,[20,111],"Coronary Artery Disease",[89],{"trials":114,"activeCount":50},[],{"intervention":116,"totalTrials":29,"cells":117},"Levothyroxine",{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":138},{"trials":119,"activeCount":50},[],{"trials":121,"activeCount":50},[],{"trials":123,"activeCount":50},[],{"trials":125,"activeCount":50},[],{"trials":127,"activeCount":50},[128],{"nctId":129,"briefTitle":130,"status":104,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT01647750","Study of Optimal Replacement of Thyroxine in the Elderly",[43],"2014-08","2012-08",48,[136],"Hypothyroidism",[116,116],{"trials":139,"activeCount":50},[],{"intervention":141,"totalTrials":29,"cells":142},"Nitrofurantoin or Trimethoprim or Cefalexin",{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":163},{"trials":144,"activeCount":50},[],{"trials":146,"activeCount":50},[],{"trials":148,"activeCount":50},[],{"trials":150,"activeCount":50},[],{"trials":152,"activeCount":50},[153],{"nctId":154,"briefTitle":155,"status":104,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":162},"NCT02145338","Antibiotic Prophylaxis for Clean Intermittent Catheterisation",[43],"2017-02-22","2013-09",404,[161],"Urinary Tract Infections, Recurrent",[141],{"trials":164,"activeCount":50},[],{"intervention":166,"totalTrials":29,"cells":167},"Capecitabine",{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":176,"NA":191},{"trials":169,"activeCount":50},[],{"trials":171,"activeCount":50},[],{"trials":173,"activeCount":50},[],{"trials":175,"activeCount":50},[],{"trials":177,"activeCount":50},[178],{"nctId":179,"briefTitle":180,"status":181,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":190},"NCT03465202","Association of Capecitabine Pharmacokinetics and Toxicity With Aging","UNKNOWN",[43],"2018-05","2019-11","2016-05",100,[188,189],"Breast Cancer","Colorectal Cancer",[166],{"trials":192,"activeCount":50},[],{"intervention":194,"totalTrials":29,"cells":195},"Donepezil",{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":214,"NA":216},{"trials":197,"activeCount":50},[],{"trials":199,"activeCount":50},[],{"trials":201,"activeCount":50},[],{"trials":203,"activeCount":50},[204],{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":213},"NCT01014858","Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease","TERMINATED",[42],"2014-09","2013-01",64,[18],[194],{"trials":215,"activeCount":50},[],{"trials":217,"activeCount":50},[],{"intervention":219,"totalTrials":29,"cells":220},"carbimazole",{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":242,"NA":244},{"trials":222,"activeCount":50},[],{"trials":224,"activeCount":50},[],{"trials":226,"activeCount":50},[],{"trials":228,"activeCount":50},[229],{"nctId":230,"briefTitle":231,"status":104,"phases":232,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":239},"NCT01436994","Antithyroid Drug Treatment of Thyrotoxicosis in Young People",[42],"2014-12","2015-11","2004-07",81,[238],"Paediatric Thyrotoxicosis",[219,240,241],"propylthiouracil","thyroxine",{"trials":243,"activeCount":50},[],{"trials":245,"activeCount":50},[],{"intervention":240,"totalTrials":29,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":260,"NA":262},{"trials":249,"activeCount":50},[],{"trials":251,"activeCount":50},[],{"trials":253,"activeCount":50},[],{"trials":255,"activeCount":50},[256],{"nctId":230,"briefTitle":231,"status":104,"phases":257,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":258,"interventions":259},[42],[238],[219,240,241],{"trials":261,"activeCount":50},[],{"trials":263,"activeCount":50},[],{"intervention":241,"totalTrials":29,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":278,"NA":280},{"trials":267,"activeCount":50},[],{"trials":269,"activeCount":50},[],{"trials":271,"activeCount":50},[],{"trials":273,"activeCount":50},[274],{"nctId":230,"briefTitle":231,"status":104,"phases":275,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":276,"interventions":277},[42],[238],[219,240,241],{"trials":279,"activeCount":50},[],{"trials":281,"activeCount":50},[],{"intervention":283,"totalTrials":29,"cells":284},"Sacubitril\u002FValsartan",{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":304,"NA":306},{"trials":286,"activeCount":50},[],{"trials":288,"activeCount":50},[],{"trials":290,"activeCount":50},[],{"trials":292,"activeCount":50},[293],{"nctId":294,"briefTitle":295,"status":104,"phases":296,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},"NCT05366101","Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy",[41,42],"2022-02-28","2022-03-31","2019-04-01",168,[302],"Hypertrophic Cardiomyopathy",[283],{"trials":305,"activeCount":50},[],{"trials":307,"activeCount":50},[],{"intervention":309,"totalTrials":29,"cells":310},"Losartan",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":329,"NA":331},{"trials":312,"activeCount":50},[],{"trials":314,"activeCount":50},[],{"trials":316,"activeCount":50},[],{"trials":318,"activeCount":50},[319],{"nctId":320,"briefTitle":321,"status":104,"phases":322,"primaryCompletion":323,"completion":233,"start":324,"enrollment":325,"conditions":326,"interventions":328},"NCT01051219","Anti-Fibrotic Effects of Losartan In Nash Evaluation Study",[42],"2014-11","2011-05",45,[327],"Nonalcoholic Steatohepatitis",[309],{"trials":330,"activeCount":50},[],{"trials":332,"activeCount":50},[],{"intervention":334,"totalTrials":29,"cells":335},"Omeprazole",{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":352,"PHASE4":354,"NA":356},{"trials":337,"activeCount":50},[],{"trials":339,"activeCount":50},[],{"trials":341,"activeCount":50},[342],{"nctId":343,"briefTitle":344,"status":104,"phases":345,"primaryCompletion":346,"completion":346,"start":347,"enrollment":325,"conditions":348,"interventions":350},"NCT02085018","Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)",[41],"2016-09-27","2014-03-28",[349],"Idiopathic Pulmonary Fibrosis",[334,351],"Matched placebo",{"trials":353,"activeCount":50},[],{"trials":355,"activeCount":50},[],{"trials":357,"activeCount":50},[],{"intervention":351,"totalTrials":29,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":361,"activeCount":50},[],{"trials":363,"activeCount":50},[],{"trials":365,"activeCount":50},[366],{"nctId":343,"briefTitle":344,"status":104,"phases":367,"primaryCompletion":346,"completion":346,"start":347,"enrollment":325,"conditions":368,"interventions":369},[41],[349],[334,351],{"trials":371,"activeCount":50},[],{"trials":373,"activeCount":50},[],{"trials":375,"activeCount":50},[],{"intervention":377,"totalTrials":29,"cells":378},"Ciclosporin",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":397,"PHASE4":399,"NA":401},{"trials":380,"activeCount":50},[],{"trials":382,"activeCount":50},[],{"trials":384,"activeCount":50},[385],{"nctId":386,"briefTitle":387,"status":104,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":395},"NCT02390674","Ciclosporin to Reduce Reperfusion Injury in Primary PCI",[41],"2017-04","2017-11-11","2015-03",54,[394],"Myocardial Reperfusion Injury",[377,396],"Saline",{"trials":398,"activeCount":50},[],{"trials":400,"activeCount":50},[],{"trials":402,"activeCount":50},[],{"intervention":396,"totalTrials":29,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":406,"activeCount":50},[],{"trials":408,"activeCount":50},[],{"trials":410,"activeCount":50},[411],{"nctId":386,"briefTitle":387,"status":104,"phases":412,"primaryCompletion":389,"completion":390,"start":391,"enrollment":392,"conditions":413,"interventions":414},[41],[394],[377,396],{"trials":416,"activeCount":50},[],{"trials":418,"activeCount":50},[],{"trials":420,"activeCount":50},[],{"intervention":422,"totalTrials":29,"cells":423},"bleomycin sulfate",{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":445,"PHASE4":447,"NA":449},{"trials":425,"activeCount":50},[],{"trials":427,"activeCount":50},[],{"trials":429,"activeCount":50},[430],{"nctId":431,"briefTitle":432,"status":104,"phases":433,"primaryCompletion":106,"completion":106,"start":434,"enrollment":435,"conditions":436,"interventions":438},"NCT00079105","A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years",[41],"2004-01",175,[437],"Lymphoma",[422,439,440,441,442,443,444],"cyclophosphamide","etoposide","mitoxantrone hydrochloride","prednisolone","procarbazine hydrochloride","vinblastine sulfate",{"trials":446,"activeCount":50},[],{"trials":448,"activeCount":50},[],{"trials":450,"activeCount":50},[],{"intervention":439,"totalTrials":29,"cells":452},{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":463,"PHASE4":465,"NA":467},{"trials":454,"activeCount":50},[],{"trials":456,"activeCount":50},[],{"trials":458,"activeCount":50},[459],{"nctId":431,"briefTitle":432,"status":104,"phases":460,"primaryCompletion":106,"completion":106,"start":434,"enrollment":435,"conditions":461,"interventions":462},[41],[437],[422,439,440,441,442,443,444],{"trials":464,"activeCount":50},[],{"trials":466,"activeCount":50},[],{"trials":468,"activeCount":50},[],{"intervention":440,"totalTrials":29,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":472,"activeCount":50},[],{"trials":474,"activeCount":50},[],{"trials":476,"activeCount":50},[477],{"nctId":431,"briefTitle":432,"status":104,"phases":478,"primaryCompletion":106,"completion":106,"start":434,"enrollment":435,"conditions":479,"interventions":480},[41],[437],[422,439,440,441,442,443,444],{"trials":482,"activeCount":50},[],{"trials":484,"activeCount":50},[],{"trials":486,"activeCount":50},[],{"intervention":441,"totalTrials":29,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":490,"activeCount":50},[],{"trials":492,"activeCount":50},[],{"trials":494,"activeCount":50},[495],{"nctId":431,"briefTitle":432,"status":104,"phases":496,"primaryCompletion":106,"completion":106,"start":434,"enrollment":435,"conditions":497,"interventions":498},[41],[437],[422,439,440,441,442,443,444],{"trials":500,"activeCount":50},[],{"trials":502,"activeCount":50},[],{"trials":504,"activeCount":50},[],{"intervention":442,"totalTrials":29,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":508,"activeCount":50},[],{"trials":510,"activeCount":50},[],{"trials":512,"activeCount":50},[513],{"nctId":431,"briefTitle":432,"status":104,"phases":514,"primaryCompletion":106,"completion":106,"start":434,"enrollment":435,"conditions":515,"interventions":516},[41],[437],[422,439,440,441,442,443,444],{"trials":518,"activeCount":50},[],{"trials":520,"activeCount":50},[],{"trials":522,"activeCount":50},[],{"intervention":443,"totalTrials":29,"cells":524},{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":535,"PHASE4":537,"NA":539},{"trials":526,"activeCount":50},[],{"trials":528,"activeCount":50},[],{"trials":530,"activeCount":50},[531],{"nctId":431,"briefTitle":432,"status":104,"phases":532,"primaryCompletion":106,"completion":106,"start":434,"enrollment":435,"conditions":533,"interventions":534},[41],[437],[422,439,440,441,442,443,444],{"trials":536,"activeCount":50},[],{"trials":538,"activeCount":50},[],{"trials":540,"activeCount":50},[],{"intervention":444,"totalTrials":29,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":544,"activeCount":50},[],{"trials":546,"activeCount":50},[],{"trials":548,"activeCount":50},[549],{"nctId":431,"briefTitle":432,"status":104,"phases":550,"primaryCompletion":106,"completion":106,"start":434,"enrollment":435,"conditions":551,"interventions":552},[41],[437],[422,439,440,441,442,443,444],{"trials":554,"activeCount":50},[],{"trials":556,"activeCount":50},[],{"trials":558,"activeCount":50},[],{"intervention":560,"totalTrials":29,"cells":561},"Leukine",{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":580,"PHASE4":582,"NA":584},{"trials":563,"activeCount":50},[],{"trials":565,"activeCount":50},[],{"trials":567,"activeCount":50},[568],{"nctId":569,"briefTitle":570,"status":104,"phases":571,"primaryCompletion":572,"completion":573,"start":133,"enrollment":211,"conditions":574,"interventions":578},"NCT01653665","Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?",[40,41],"2015-01","2015-02",[575,576,577],"Critical Illness","Sepsis","Immuno-suppression",[560,579],"Normal Saline",{"trials":581,"activeCount":50},[],{"trials":583,"activeCount":50},[],{"trials":585,"activeCount":50},[],{"intervention":579,"totalTrials":29,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":589,"activeCount":50},[],{"trials":591,"activeCount":50},[],{"trials":593,"activeCount":50},[594],{"nctId":569,"briefTitle":570,"status":104,"phases":595,"primaryCompletion":572,"completion":573,"start":133,"enrollment":211,"conditions":596,"interventions":597},[40,41],[575,576,577],[560,579],{"trials":599,"activeCount":50},[],{"trials":601,"activeCount":50},[],{"trials":603,"activeCount":50},[],{"intervention":605,"totalTrials":29,"cells":606},"Ticagrelor",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":624,"PHASE4":626,"NA":628},{"trials":608,"activeCount":50},[],{"trials":610,"activeCount":50},[],{"trials":612,"activeCount":50},[613],{"nctId":614,"briefTitle":615,"status":104,"phases":616,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":622},"NCT03487406","Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)",[41],"2017-11","2015-09",120,[621],"Chronic Obstructive Pulmonary Disease (COPD)",[605,623],"Aspirin",{"trials":625,"activeCount":50},[],{"trials":627,"activeCount":50},[],{"trials":629,"activeCount":50},[],{"intervention":623,"totalTrials":29,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":642,"PHASE4":644,"NA":646},{"trials":633,"activeCount":50},[],{"trials":635,"activeCount":50},[],{"trials":637,"activeCount":50},[638],{"nctId":614,"briefTitle":615,"status":104,"phases":639,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":640,"interventions":641},[41],[621],[605,623],{"trials":643,"activeCount":50},[],{"trials":645,"activeCount":50},[],{"trials":647,"activeCount":50},[],{"intervention":649,"totalTrials":29,"cells":650},"Bezafibrate",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":665,"PHASE4":667,"NA":669},{"trials":652,"activeCount":50},[],{"trials":654,"activeCount":50},[],{"trials":656,"activeCount":50},[657],{"nctId":658,"briefTitle":659,"status":104,"phases":660,"primaryCompletion":661,"completion":662,"start":618,"enrollment":8,"conditions":663,"interventions":664},"NCT02398201","A Study of Bezafibrate in Mitochondrial Myopathy",[41],"2017-01","2017-03-23",[24],[649],{"trials":666,"activeCount":50},[],{"trials":668,"activeCount":50},[],{"trials":670,"activeCount":50},[],{"intervention":672,"totalTrials":29,"cells":673},"Rituximab",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":692,"PHASE4":694,"NA":696},{"trials":675,"activeCount":50},[],{"trials":677,"activeCount":50},[],{"trials":679,"activeCount":50},[680],{"nctId":681,"briefTitle":682,"status":104,"phases":683,"primaryCompletion":684,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":691},"NCT02376335","B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis",[41],"2016-03","2016-09","2012-10",71,[689,690],"Fatigue","Primary Biliary Cirrhosis",[672],{"trials":693,"activeCount":50},[],{"trials":695,"activeCount":50},[],{"trials":697,"activeCount":50},[],{"intervention":699,"totalTrials":29,"cells":700},"Lisinopril",{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":715,"PHASE3":717,"PHASE4":719,"NA":721},{"trials":702,"activeCount":50},[],{"trials":704,"activeCount":50},[705],{"nctId":706,"briefTitle":707,"status":104,"phases":708,"primaryCompletion":709,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":714},"NCT01066572","Paramedic Initiated Lisinopril For Acute Stroke Treatment",[40],"2011-12","2010-10",14,[713],"Stroke",[699],{"trials":716,"activeCount":50},[],{"trials":718,"activeCount":50},[],{"trials":720,"activeCount":50},[],{"trials":722,"activeCount":50},[],{"intervention":724,"totalTrials":29,"cells":725},"Sustanon",{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":736},{"trials":727,"activeCount":50},[],{"trials":729,"activeCount":50},[],{"trials":731,"activeCount":50},[],{"trials":733,"activeCount":50},[],{"trials":735,"activeCount":50},[],{"trials":737,"activeCount":50},[738],{"nctId":739,"briefTitle":740,"status":104,"phases":741,"primaryCompletion":742,"completion":743,"start":234,"enrollment":744,"conditions":745,"interventions":747},"NCT02571205","Testosterone Therapy for Pubertal Delay in Duchenne Muscular Dystrophy",[],"2019-02","2019-03",15,[746],"Duchenne Muscular Dystrophy",[724],{"intervention":749,"totalTrials":29,"cells":750},"Ramipril",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":752,"activeCount":50},[],{"trials":754,"activeCount":50},[],{"trials":756,"activeCount":50},[],{"trials":758,"activeCount":50},[],{"trials":760,"activeCount":50},[],{"trials":762,"activeCount":50},[763],{"nctId":764,"briefTitle":765,"status":104,"phases":766,"primaryCompletion":767,"completion":767,"start":768,"enrollment":769,"conditions":770,"interventions":774},"NCT01504828","Cardiac Energetics and Function in Normal Human Ageing",[44],"2015-12","2012-07",135,[771,772,773],"Left Ventricular Function Systolic Dysfunction","Left Ventricular Function Diastolic Dysfunction","Ageing",[749],{"intervention":776,"totalTrials":29,"cells":777},"DMARD cessation",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":779,"activeCount":50},[],{"trials":781,"activeCount":50},[],{"trials":783,"activeCount":50},[],{"trials":785,"activeCount":50},[],{"trials":787,"activeCount":50},[],{"trials":789,"activeCount":50},[790],{"nctId":791,"briefTitle":792,"status":104,"phases":793,"primaryCompletion":794,"completion":794,"start":132,"enrollment":795,"conditions":796,"interventions":797},"NCT02219347","Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)",[44],"2017-08",74,[15],[776]]